PURPOSE: To correlate the response of topical dorzolamide (Trusopt; Merck) in patients with X-linked retinoschisis (XLRS) with genotype. METHODS: We carried out a retrospective evaluation of four patients (seven eyes) with XLRS, treated with topical dorzolamide. The change in best-corrected visual acuity (VA) and central macular thickness (CMT; central 1 mm subfield thickness) from optical coherence tomography (OCT) was analysed over the follow-up period, using Student's t-test. Each patient also had genetic analysis for mutations in the retinoschisisgene (RS1). RESULTS: The mean age at the start of treatment was 14.7±11 years, and mean follow-up duration was 21.7±7.7 months. Mean CMT at the final follow-up was significantly better than at baseline (291±123 vs 352±119 μm, P=0.007); however, mean VA was worse (0.38±0.25 vs 0.31±0.24 logMAR score, P=0.041). All four patients had a mutation in the RS1gene; there was no apparent association between the type of mutation and the response to topical dorzolamide. CONCLUSION: Topical dorzolamide may have some effect in reducing central macular thickness in patients with XLRS, but this does not necessarily correlate with improvement in VA. In our case series, genotypic information did not predict the response to this treatment.
PURPOSE: To correlate the response of topical dorzolamide (Trusopt; Merck) in patients with X-linked retinoschisis (XLRS) with genotype. METHODS: We carried out a retrospective evaluation of four patients (seven eyes) with XLRS, treated with topical dorzolamide. The change in best-corrected visual acuity (VA) and central macular thickness (CMT; central 1 mm subfield thickness) from optical coherence tomography (OCT) was analysed over the follow-up period, using Student's t-test. Each patient also had genetic analysis for mutations in the retinoschisisgene (RS1). RESULTS: The mean age at the start of treatment was 14.7±11 years, and mean follow-up duration was 21.7±7.7 months. Mean CMT at the final follow-up was significantly better than at baseline (291±123 vs 352±119 μm, P=0.007); however, mean VA was worse (0.38±0.25 vs 0.31±0.24 logMAR score, P=0.041). All four patients had a mutation in the RS1gene; there was no apparent association between the type of mutation and the response to topical dorzolamide. CONCLUSION: Topical dorzolamide may have some effect in reducing central macular thickness in patients with XLRS, but this does not necessarily correlate with improvement in VA. In our case series, genotypic information did not predict the response to this treatment.
Authors: Tao Wang; Caroline T Waters; Alex M K Rothman; Tracy J Jakins; Karin Römisch; Dorothy Trump Journal: Hum Mol Genet Date: 2002-11-15 Impact factor: 6.150
Authors: Bernhard H F Weber; Heinrich Schrewe; Laurie L Molday; Andrea Gehrig; Karen L White; Mathias W Seeliger; Gesine B Jaissle; Christoph Friedburg; Ernst Tamm; Robert S Molday Journal: Proc Natl Acad Sci U S A Date: 2002-04-30 Impact factor: 11.205
Authors: C Grayson; S N Reid; J A Ellis; A Rutherford; J C Sowden; J R Yates; D B Farber; D Trump Journal: Hum Mol Genet Date: 2000-07-22 Impact factor: 6.150
Authors: Yong Zeng; Yuichiro Takada; Sten Kjellstrom; Kelaginamane Hiriyanna; Atsuhiro Tanikawa; Eric Wawrousek; Nizar Smaoui; Rafael Caruso; Ronald A Bush; Paul A Sieving Journal: Invest Ophthalmol Vis Sci Date: 2004-09 Impact factor: 4.799
Authors: Guo-Jie Ye; Ewa Budzynski; Peter Sonnentag; Paul E Miller; Alok K Sharma; James N Ver Hoeve; Kellie Howard; David R Knop; Martha Neuringer; Trevor McGill; Jonathan Stoddard; Jeffrey D Chulay Journal: Hum Gene Ther Clin Dev Date: 2015-09 Impact factor: 5.032
Authors: Brett G Jeffrey; Catherine A Cukras; Susan Vitale; Amy Turriff; Kristin Bowles; Paul A Sieving Journal: Transl Vis Sci Technol Date: 2014-10-03 Impact factor: 3.283
Authors: Maria Silvana Galantuomo; Maurizio Fossarello; Alberto Cuccu; Roberta Farci; Markus N Preising; Birgit Lorenz; Pietro Emanuele Napoli Journal: Clin Ophthalmol Date: 2016-11-25